Item 8.01 Other Events.

On January 21, 2021, Ultragenyx Pharmaceutical Inc. (the "Company") issued a press release (the "Press Release") announcing that the U.S. Food and Drug Administration has cleared the Company's Investigational New Drug (IND) application for UX701, an investigational AAV9 gene therapy being evaluated for the treatment of Wilson Disease. A copy of the Press Release is filed as Exhibit 99.1

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits



Exhibit No. Description
99.1          Press Release, dated January 21, 2021.
104         The cover page from the Company's Current Report on Form 8-K dated
            January 21, 2021 formatted in Inline XBRL.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses